News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio -
-
-
COMMUNIQUÉ DE PRESSE
Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Formycon AG publishes nine-month results, reaffirms 2025 guidance with strong pipeline progress and partnerships. Read about fiscal performance and strategic advancements -
-
